Compare MOFG & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MOFG | EYPT |
|---|---|---|
| Founded | 1934 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 861.6M | 1.5B |
| IPO Year | N/A | 2005 |
| Metric | MOFG | EYPT |
|---|---|---|
| Price | $45.42 | $15.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $40.50 | $28.75 |
| AVG Volume (30 Days) | 181.9K | ★ 1.1M |
| Earning Date | 01-30-2026 | 03-04-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.81 | N/A |
| Revenue | ★ $221,843,000.00 | $42,339,000.00 |
| Revenue This Year | $241.79 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $14.78 | ★ N/A |
| Revenue Growth | ★ 504.86 | N/A |
| 52 Week Low | $24.62 | $3.91 |
| 52 Week High | $42.67 | $19.11 |
| Indicator | MOFG | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 73.81 | 40.26 |
| Support Level | $40.53 | $14.50 |
| Resistance Level | $42.67 | $17.61 |
| Average True Range (ATR) | 1.45 | 1.04 |
| MACD | 0.46 | -0.34 |
| Stochastic Oscillator | 98.51 | 19.00 |
MidWestOne Financial Group Inc is a bank holding company engaged in delivering relationship-based business and personal banking products and services. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. The Bank offers its products and services through its network of full-service banking offices. the Bank's investments services department offers financial planning, investment advisory, and retail securities brokerage services.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.